Retinoic Acid Promotes Interleukin-4 Plasmid-Dimethylsulfoxide Topical Transdermal Delivery for Treatment of Psoriasis

키워드

참고문헌 (34)

1. Reich A, "Genetic and immunological aspects of the pathogenesis of psoriasis", Wiad Lek, 60, pp.270~276 (2007)
2. Boniface K, "Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis of psoriasis", Eur Cytokine Netw, 16, pp.309~319 (2005)
3. Lowes MA, "Pathogenesis and therapy of psoriasis", Nature, 445, pp.866~873 (2007)
4. Pastore S, "Chemokine networks in inflammatory skin diseases", Eur J Dermatol, 14, pp.203~208 (2004)
5. Harrington LE, "Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 line", Nat Immunol, 6, pp.1123~1132 (2005)
6. Ghoreschi K, "Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease", Nat Med, 9, pp.40~46 (2003)
7. Ren X, "Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model", Dermatology, 219, pp.232~238 (2009)
8. Chen X, "Retinoic acid and dimethyl sulfoxide promote efficient delivery of transgenes to mouse skin by topically transdermal penetration", Drug Deliv, 17, pp.385~390 (2010)
9. Lee VH, "Advanced drug delivery reviews: cornerstone in the stimulation and dissemination of innovative drug delivery research", Adv Drug Deliv Rev, 56, pp.1~2 (2004)
10. Zhang Y, "A novel transdermal plasmid-dimethylsulfoxide delivery technique for treatment of psoriasis", Dermatology, 221, pp.84~92 (2010)
11. Chen Q, "Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells", Exp Cell Res, 297, pp.68~81 (2004)
12. Karlsson T, "Topical retinoic acid alters the expression of cellular retinoic acid-binding protein-I and cellular retinoic acid-binding protein-II in non-lesional but not lesional psoriatic skin", Exp Dermatol, 11, pp.143~152 (2002)
13. Domashenko A, "Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex", Nat Biotechnol, 18, pp.420~423 (2000)
14. Park KM, "All-trans-retinoic acid (ATRA)-grafted polymeric gene carriers for nuclear translocation and cell growth control", Biomaterials, 30, pp.2642~2652 (2009)
15. Xia YP, "Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis", Blood, 102, pp.161~168 (2003)
16. Baker BS, "Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?", Br J Dermatol, 126, pp.105~110 (1992)
17. Schön MP, "Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation", Nat Med, 8, pp.366~372 (2002)
18. Grailer JJ, "L-selectin: role in regulating homeostasis and cutaneous inflammation", J Dermatol Sci, 56, pp.141~147 (2009)
19. Nelson AA, "New treatments for psoriasis: which biologic is best?", J Dermatolog Treat, 17, pp.96~107 (2006)
20. Pariser DM, "National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity", Arch Dermatol, 143, pp.239~242 (2007)
21. Liu Y, "A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci", PLoS Genet, 4, pp.e1000041~ (2008)
22. Gonze D, "Stochastic models for circadian rhythms: effect of molecular noise on periodic and chaotic behaviour", C R Biol, 326, pp.189~203 (2003)
23. Catalina MD, "Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation: participation of E- and P- but not L-selectin", Blood, 93, pp.580~589 (1999)
24. Sigmundsdottir H, "The effects of ultraviolet B treatment on the expression of adhesion molecules by circulating T lymphocytes in psoriasis", Br J Dermatol, 148, pp.996~1000 (2003)
25. Eşrefoğlu M, "Ultrastructural findings and tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression in psoriasis patients before and after oral cyclosporin A therapy", Ultrastruct Pathol, 30, pp.95~102 (2006)
26. Creamer D, "Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis", Br J Dermatol, 136, pp.859~865 (1997)
27. Heidenreich R, "Angiogenesis drives psoriasis pathogenesis", Int J Exp Pathol, 90, pp.232~248 (2009)
28. Bovenschen HJ, "Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study", Br J Dermatol, 156, pp.263~270 (2007)
29. Geria AN, "Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne", Curr Opin Investig Drugs, 9, pp.1228~1237 (2008)
30. Mrass P, "Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids", Cancer Res, 64, pp.6542~6548 (2004)
31. Colucci M, "New insights of dimethyl sulphoxide effects (DMSO) on experimental in vivo models of nociception and inflammation", Pharmacol Res, 57, pp.419~425 (2008)
32. Li J, "Expression of Th17cytokines in skin lesions of patients with psoriasis", J Huazhong Univ Sci Technolog Med Sci, 27, pp.330~332 (2007)
33. Kagami S, "Circulating Th17, Th22, and Th1 cells are increased in psoriasis", J Invest Dermatol, 130, pp.1373~1383 (2010)
34. Zaba LC, "Psoriasis is characterized by accumulation of immunostimulatory and Th1", Th17 cellpolarizing myeloid dendritic cells, 2009, pp.129, 79~88

관련 논문AI추천